100
Participants
Start Date
July 13, 2021
Primary Completion Date
March 29, 2022
Study Completion Date
July 26, 2022
AZD1222
"Active substance: ChAdOx1 nCoV-19, a replicant-deficient simian adenoviral vector in the amount of 5 х 10\^10 particles (nominal) per dose (unit dose strength \> 0.7 × 10\^11 vp/mL).~Solution for intramuscular injection, supplied in vials in a carton box"
rAd26-S
"Component I (Dose 1) - (0.5 ml per dose) contains:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 10\^11 particles per dose (unit dose strength 1 × 10\^11 vp/0.5 mL) .~Solution for intramuscular injection, supplied in vials in containers"
Tawam Hospital, Al Ain City
Lead Sponsor
Collaborators (1)
AstraZeneca
INDUSTRY
R-Pharm
INDUSTRY